Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

77 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Transcriptomic and genomic heterogeneity in blastic plasmacytoid dendritic cell neoplasms: from ontogeny to oncogenesis.
Renosi F, Roggy A, Giguelay A, Soret L, Viailly PJ, Cheok M, Biichle S, Angelot-Delettre F, Asnafi V, Macintyre E, Geffroy S, Callanan M, Petrella T, Deconinck E, Daguindau E, Harrivel V, Bouyer S, Salaun V, Saussoy P, Feuillard J, Fuseau P, Saas P, Adotévi O, Jardin F, Ferrand C, Preudhomme C, Colinge J, Roumier C, Garnache-Ottou F. Renosi F, et al. Among authors: cheok m. Blood Adv. 2021 Mar 9;5(5):1540-1551. doi: 10.1182/bloodadvances.2020003359. Blood Adv. 2021. PMID: 33687433 Free PMC article.
TET2 mutation is an independent favorable prognostic factor in myelodysplastic syndromes (MDSs).
Kosmider O, Gelsi-Boyer V, Cheok M, Grabar S, Della-Valle V, Picard F, Viguié F, Quesnel B, Beyne-Rauzy O, Solary E, Vey N, Hunault-Berger M, Fenaux P, Mansat-De Mas V, Delabesse E, Guardiola P, Lacombe C, Vainchenker W, Preudhomme C, Dreyfus F, Bernard OA, Birnbaum D, Fontenay M; Groupe Francophone des Myélodysplasies. Kosmider O, et al. Among authors: cheok m. Blood. 2009 Oct 8;114(15):3285-91. doi: 10.1182/blood-2009-04-215814. Epub 2009 Aug 7. Blood. 2009. PMID: 19666869 Free article.
Pharmacogenomics in acute myeloid leukemia.
Roumier C, Cheok MH. Roumier C, et al. Pharmacogenomics. 2009 Nov;10(11):1839-51. doi: 10.2217/pgs.09.130. Pharmacogenomics. 2009. PMID: 19891558 Review.
Incidence and prognostic value of TET2 alterations in de novo acute myeloid leukemia achieving complete remission.
Nibourel O, Kosmider O, Cheok M, Boissel N, Renneville A, Philippe N, Dombret H, Dreyfus F, Quesnel B, Geffroy S, Quentin S, Roche-Lestienne C, Cayuela JM, Roumier C, Fenaux P, Vainchenker W, Bernard OA, Soulier J, Fontenay M, Preudhomme C. Nibourel O, et al. Among authors: cheok m. Blood. 2010 Aug 19;116(7):1132-5. doi: 10.1182/blood-2009-07-234484. Epub 2010 May 20. Blood. 2010. PMID: 20489055 Free article.
Clinical impact of gene mutations and lesions detected by SNP-array karyotyping in acute myeloid leukemia patients in the context of gemtuzumab ozogamicin treatment: results of the ALFA-0701 trial.
Renneville A, Abdelali RB, Chevret S, Nibourel O, Cheok M, Pautas C, Duléry R, Boyer T, Cayuela JM, Hayette S, Raffoux E, Farhat H, Boissel N, Terre C, Dombret H, Castaigne S, Preudhomme C. Renneville A, et al. Among authors: cheok m. Oncotarget. 2014 Feb 28;5(4):916-32. doi: 10.18632/oncotarget.1536. Oncotarget. 2014. PMID: 24659740 Free PMC article. Clinical Trial.
Classification of CEBPA mutated acute myeloid leukemia by GATA2 mutations.
Marceau-Renaut A, Guihard S, Castaigne S, Dombret H, Preudhomme C, Cheok M. Marceau-Renaut A, et al. Among authors: cheok m. Am J Hematol. 2015 May;90(5):E93-4. doi: 10.1002/ajh.23949. Epub 2015 Feb 17. Am J Hematol. 2015. PMID: 25611491 Free article. Clinical Trial. No abstract available.
Defective NK Cells in Acute Myeloid Leukemia Patients at Diagnosis Are Associated with Blast Transcriptional Signatures of Immune Evasion.
Khaznadar Z, Boissel N, Agaugué S, Henry G, Cheok M, Vignon M, Geromin D, Cayuela JM, Castaigne S, Pautas C, Raffoux E, Lachuer J, Sigaux F, Preudhomme C, Dombret H, Dulphy N, Toubert A. Khaznadar Z, et al. Among authors: cheok m. J Immunol. 2015 Sep 15;195(6):2580-90. doi: 10.4049/jimmunol.1500262. Epub 2015 Aug 5. J Immunol. 2015. PMID: 26246143
IDH1/2 but not DNMT3A mutations are suitable targets for minimal residual disease monitoring in acute myeloid leukemia patients: a study by the Acute Leukemia French Association.
Debarri H, Lebon D, Roumier C, Cheok M, Marceau-Renaut A, Nibourel O, Geffroy S, Helevaut N, Rousselot P, Gruson B, Gardin C, Chretien ML, Sebda S, Figeac M, Berthon C, Quesnel B, Boissel N, Castaigne S, Dombret H, Renneville A, Preudhomme C. Debarri H, et al. Among authors: cheok m. Oncotarget. 2015 Dec 8;6(39):42345-53. doi: 10.18632/oncotarget.5645. Oncotarget. 2015. PMID: 26486081 Free PMC article.
Tetraspanin CD81 is an adverse prognostic marker in acute myeloid leukemia.
Boyer T, Guihard S, Roumier C, Peyrouze P, Gonzales F, Berthon C, Quesnel B, Preudhomme C, Behal H, Duhamel A, Roche-Lestienne C, Cheok M. Boyer T, et al. Among authors: cheok m. Oncotarget. 2016 Sep 20;7(38):62377-62385. doi: 10.18632/oncotarget.11481. Oncotarget. 2016. PMID: 27566555 Free PMC article.
77 results